Luxa Biotechnology gives first dose to patients in clinical trial

 In the clinical trial phase 1/2a for the development of a treatment for dry macular degeneration, Luxa Biotechnology gives the first dose to patients.  

• https://www.businesswire.com/news/home/20220524005126/en/

• https://www.biospace.com/article/releases/luxa-bio-announces-first-participant-dosed-in-phase-1-2a-clinical-trial-of-adult-rpesc-rpe-4w-for-dry-age-related-macular-degeneration/

• https://finance.yahoo.com/news/luxa-bio-announces-first-participant-120000860.html

• https://www.fightingblindness.org/research/luxa-doses-first-participant-in-clinical-trial-of-rpe-stem-cells-for-dry-amd-patients-260

• https://pharma-trend.com/en/luxa-bio-announces-first-participant-dosed-in-phase-1-2a-clinical-trial-of-adult-rpesc-rpe-4w-for-dry-age-related-macular-degeneration/

• https://www.iqstock.news/n/luxa-bio-announces-participant-dosed-phase-2a-clinical-trial-adult-rpesc-rpe-3944173/